Skip to main content

Table 2 Coagulation parameters during the study

From: Four-day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis

 

At baseline

After bolus application

At end of treatment period

 

Placebo

Antithrombin

Placebo

Antithrombin

Placebo

Antithrombin

Prothrombin time (%)

70 (38–95)

60 (38–103)

60 (39–84)

60 (38–82)

77 (5–10)

64 (5–9)

Activated partial thromboplastin time (s)

42 (27–53)

46 (33–60)

44 (32–67)

53 (34–77)

44 (29–74)

47 (34–95)

Fibrinogen (mg/dl)

587 (262–821)

557 (229–841)

595 (283–770)

505 (313–704)

622 (115–842)

538 (200–868)

Platelet count (1,000/ml)

225 (86–581)

179 (71–742)

170 (81–358)

154 (61–730)

199 (63–418)

115 (14–475)

Antithrombin (%)

68 (31–113)

55 (27–99)

54 (22–108)

110* (43–350)

86 (29–87)

141* (110–149)

Reaction time (mm)

7 (6–15)

9 (6–16)

8 (5–15)

11 (7–25)

8 (5–19)

11 (8–18)

Coagulation time (mm)

3 (2–4)

3 (2–8)

3 (2–4)

3 (2–7)

2 (1–8)

4 (3–10)

Alpha angle (°)

74 (64–80)

71 (50–80)

69 (64–81)

70 (36–79)

76 (43–81)

64 (46–76)

Maximum amplitude (mm)

69 (57–79)

66 (49–81)

66 (60–74)

70 (49–83)

71 (38–82)

72 (38–82)

Abciximab maximum amplitude (mm)

29 (15–49)

29 (13–49)

29 (23–45)

28 (12–45)

33 (14–48)

31 (7–48)

  1. Data presented as the median (minimum–maximum). Normal ranges: prothrombin time = 75–140%, activated partial thromboplastin time = 27–41 s, reaction time = 10–19 mm, coagulation time = 4–10 mm, alpha angle = 44–56°, maximum amplitude = 50–64 mm. *P ≤ 0.05 compared with placebo.